FDA approves breakthrough pancreatic cancer drug – an oncologist explains how daraxonrasib nearly doubles survival
Around 97% of patients with advanced pancreatic cancer die within five years. Researchers have figured out a way to target the mechanism that makes these tumors so deadly.
Pancreatic cancer has long been a difficult disease to treat, with a survival rate of over 97% within five years of diagnosis. The cancer's origins lie in a mutated KRAS gene, which causes the cancer cells to grow uncontrollably. Despite extensive efforts, targeting this protein has proven challenging, as it is difficult for drugs to bind to and inhibit its activity.
A new drug called daraxonrasib, approved by the FDA on August 26, 2026, may change the outlook for patients with metastatic pancreatic cancer. Unlike traditional chemotherapy, daraxonrasib works by targeting a different protein complex that helps regulate the activity of the KRAS protein. In a Phase 3 clinical trial of 500 patients, daraxonrasib nearly doubled overall survival rates, extending the time from diagnosis to death from 6.7 months to 13.2 months.
While the most common side effect is a skin rash affecting over 86% of patients, daraxonrasib caused fewer treatment discontinuations due to severe side effects compared to chemotherapy. With the FDA's approval, patients will now have access to this promising treatment, offering hope for improved outcomes and a more personalized approach to pancreatic cancer care.
Written by urgent.news from The Conversation's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
